• In early 2026, Establishment Labs Holdings announced that it had sold more than 5 million Motiva breast implant devices globally and reported fourth-quarter 2025 results with revenue growth above 25% for 2025, a 45% year-over-year revenue increase in Q4, and an expanded gross margin driven in part by its U.S. launch and minimally invasive platform.
• This combination of a major product milestone and stronger-than-expected financial performance suggests that Motiva’s U.S. adoption and procedural innovation are becoming increasingly important to Establishment Labs Holdings’ operating profile.
• We’ll now examine how this record Motiva sales milestone and stronger quarterly performance may influence Establishment Labs Holdings’ broader investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 27 best rare earth metal stocks of the very few that mine this essential strategic resource.

Establishment Labs Holdings Investment Narrative Recap

To own Establishment Labs Holdings, you need to believe that Motiva can keep gaining share in global breast aesthetics while the U.S. launch and minimally invasive platforms like Mia and Preservé help drive a path toward profitability. The 5 million Motiva device milestone and stronger Q4 2025 results reinforce U.S. adoption as the key near term catalyst, but they do not remove the biggest risk, which is continued high spending and cash use as the company scales.

The February 24, 2026 earnings release is especially relevant here, because it put numbers around this momentum: Q4 2025 revenue rose to US$64.6 million with full year sales of US$211.1 million and a sharply narrower net loss. For investors, this ties the Motiva milestone directly to the core catalyst of expanding U.S. surgeon adoption and improving gross margins, while still leaving open questions about when operating expenses and liquidity will fully realign with that growth.

Yet investors should also be aware that if heightened global scrutiny around plastics and synthetic implants intensifies, especially as Motiva volumes rise so quickly, then...

Establishment Labs Holdings' narrative projects $415.7 million revenue and $46.3 million earnings by 2029.

Uncover how Establishment Labs Holdings' forecasts yield a $89.00 fair value, a 48% upside to its current price.

Exploring Other Perspectives

While recent Motiva milestones support the consensus view, the most pessimistic analysts still saw only US$336.5 million of revenue and US$42.0 million of earnings by 2028, reminding you that opinions can diverge sharply on how regulatory and societal pressures might shape Establishment Labs’ future.

Explore 3 other fair value estimates on Establishment Labs Holdings - why the stock might be worth as much as 48% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Establishment Labs Holdings research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Establishment Labs Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Establishment Labs Holdings' overall financial health at a glance.

Seeking Other Investments?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.